DiaMedica Therapeutics Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical-stage biopharmaceutical company focused on developing novel recombinant protein therapies for serious ischemic diseases, including preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS); its lead candidate, DM199 (rinvecalinase alfa, rhKLK1), a recombinant form of human tissue kallikrein-1 protein, enhances blood flow and vascular health by increasing nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor levels to promote collateral circulation and reverse ischemic injury; the company also advances DM300, a recombinant human ulinastatin serine protease inhibitor in preclinical development for inflammatory conditions such as acute pancreatitis. Founded in 2000 and headquartered at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, DiaMedica Therapeutics operates primarily in the United States with global clinical trial sites for its pipeline programs targeting unmet needs in maternal-fetal medicine and neurology. Recent developments include the completion of Part 1a dose escalation in its Phase 2 investigator-sponsored trial (IST) for DM199 in PE with an expansion cohort enrolling at the therapeutic dose level, expected to finish in first-half 2026; screening initiation for Part 3 FGR cohort; a productive in-person pre-IND meeting with the U.S. FDA to support an upcoming IND submission for a U.S. Phase 2 study in PE and FGR; enrollment nearing 50% of the 200-patient interim target in the ReMEDy2 Phase 2/3 trial for DM199 in AIS, with analysis slated for second-half 2026; and a $30.1 million private placement of common shares closed in July 2025, boosting cash and short-term investments to $55.3 million as of September 30, 2025, providing runway into second-half 2027.
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Average Rating of “Moderate Buy” by Brokerages
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
DiaMedica Therapeutics (DMAC) Expected to Announce Earnings on Monday
Brokerages Set DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Target Price at $12.33
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
Leon Cooperman's Strategic Moves: Mr. Cooper Group Inc. Exits with -18.82% Impact
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of “Moderate Buy” by Brokerages
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA